Literature DB >> 19262119

Phenylboronic acid selectively inhibits human prostate and breast cancer cell migration and decreases viability.

Tiffany M Bradke1, Casey Hall, Stephen W Carper, George E Plopper.   

Abstract

We compared the in vitro effect of boric acid (BA) versus phenylboronic acid (PBA) on the migration of prostate and breast cancer cell lines and non-tumorigenic cells from the same tissues. Treatment at 24 hours with BA (< or =500 microM) did not inhibit chemotaxis on fibronectin in any cell line. However, treatment over the same time course with concentrations of PBA as low as 1 muM significantly inhibited cancer cell migration without effecting non-tumorigenic cell lines. The compounds did not affect cell adhesion or viability at 24 hours but did alter morphology; both decreased cancer cell viability at eight days. These results suggest that PBA is more potent than BA in targeting the metastatic and proliferative properties of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19262119      PMCID: PMC2634091          DOI: 10.4161/cam.2.3.6484

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  44 in total

Review 1.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

2.  Migration of breast epithelial cells on Laminin-5: differential role of integrins in normal and transformed cell types.

Authors:  G E Plopper; S Z Domanico; V Cirulli; W B Kiosses; V Quaranta
Journal:  Breast Cancer Res Treat       Date:  1998-09       Impact factor: 4.872

3.  Screening assay for promigratory/antimigratory compounds.

Authors:  W L Rust; J L Huff; G E Plopper
Journal:  Anal Biochem       Date:  2000-04-10       Impact factor: 3.365

Review 4.  Natural products as anticancer agents.

Authors:  S Sinha; S Jain
Journal:  Prog Drug Res       Date:  1994

Review 5.  The justification for providing dietary guidance for the nutritional intake of boron.

Authors:  F H Nielsen
Journal:  Biol Trace Elem Res       Date:  1998       Impact factor: 3.738

Review 6.  Regulation of enzymatic activity: one possible role of dietary boron in higher animals and humans.

Authors:  C D Hunt
Journal:  Biol Trace Elem Res       Date:  1998       Impact factor: 3.738

Review 7.  Prostate cancer: status of current treatments and emerging antisense-based therapies.

Authors:  Gayathri R Devi
Journal:  Curr Opin Mol Ther       Date:  2002-04

8.  Boric acid single dose pharmacokinetics after intravenous administration to man.

Authors:  J A Jansen; J Andersen; J S Schou
Journal:  Arch Toxicol       Date:  1984-03       Impact factor: 5.153

Review 9.  Multidrug resistance in human cancer.

Authors:  M Lehnert
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  An introduction to boron: history, sources, uses, and chemistry.

Authors:  W G Woods
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

View more
  12 in total

1.  Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells.

Authors:  Mehmet Korkmaz; Cigir Biray Avcı; Cumhur Gunduz; Duygu Aygunes; Burcu Erbaykent-Tepedelen
Journal:  Tumour Biol       Date:  2014-02

2.  Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration.

Authors:  Erin M McAuley; Tiffany A Bradke; George E Plopper
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

3.  Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.

Authors:  Robson Xavier Faria; Noemi de Jesus Hiller; Juliana Pimenta Salles; Jackson Antonio Lamounier Camargos Resende; Roberta Tosta Diogo; Natalia Lidmar von Ranke; Murilo Lamim Bello; Carlos Rangel Rodrigues; Helena Carla Castro; Daniela de Luna Martins
Journal:  J Bioenerg Biomembr       Date:  2019-06-29       Impact factor: 2.945

4.  Boric acid induces cytoplasmic stress granule formation, eIF2α phosphorylation, and ATF4 in prostate DU-145 cells.

Authors:  Kimberly A Henderson; Sarah E Kobylewski; Kristin E Yamada; Curtis D Eckhert
Journal:  Biometals       Date:  2014-11-26       Impact factor: 2.949

5.  Synthesis and Characterization of 8-O-Carboxymethylpyranine (CM-Pyranine) as a Bright, Violet-Emitting, Fluid-Phase Fluorescent Marker in Cell Biology.

Authors:  Eric A Legenzov; Nathaniel D A Dirda; Brian M Hagen; Joseph P Y Kao
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

6.  Multilayered Thin Films from Boronic Acid-Functional Poly(amido amine)s.

Authors:  Sry D Hujaya; Johan F J Engbersen; Jos M J Paulusse
Journal:  Pharm Res       Date:  2015-04-08       Impact factor: 4.200

7.  Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake.

Authors:  Sarah E Kobylewski; Kimberly A Henderson; Kristin E Yamada; Curtis D Eckhert
Journal:  Biol Trace Elem Res       Date:  2016-09-01       Impact factor: 3.738

8.  Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment.

Authors:  Xia Li; Xiupeng Wang; Jun Zhang; Nobutaka Hanagata; Xuebin Wang; Qunhong Weng; Atsuo Ito; Yoshio Bando; Dmitri Golberg
Journal:  Nat Commun       Date:  2017-01-06       Impact factor: 14.919

9.  In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells.

Authors:  Maja Marasovic; Sinisa Ivankovic; Ranko Stojkovic; Damir Djermic; Borivoj Galic; Mladen Milos
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

10.  Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells.

Authors:  Mateusz Psurski; Agnieszka Łupicka-Słowik; Agnieszka Adamczyk-Woźniak; Joanna Wietrzyk; Andrzej Sporzyński
Journal:  Invest New Drugs       Date:  2018-05-19       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.